Comparison · NCT01227967-sae
Combination Therapy vs Oseltamivir Monotherapy: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Combination Therapy vs Oseltamivir Monotherapy: serious adverse events. Trial comparisons, record NCT01227967-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01227967-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0446 | 0.0267 | 0.0734 | wilson | |
| Risk in group 2 | 0.0192 | 0.00884 | 0.0413 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0254 | -0.00304 | 0.056 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.32 | 0.903 | 5.96 | log | |
| Odds ratio, group 1 over group 2 | 2.38 | 0.903 | 6.28 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Combination Therapy than on Oseltamivir Monotherapy | 39.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Combination Therapy | Drug: Amantadine, Ribavirin, Oseltamivir~Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg. | 14 | 314 | EG000 |
| Group 2 | Oseltamivir Monotherapy | Drug: Oseltamivir~Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg. | 6 | 312 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events were collected throughout the conduct of the study; from Day 0 to Day 28
Source ClinicalTrials.gov
Trial
- Title
- Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
- NCT number
- NCT01227967
- Phases
- PHASE2
- Conditions
- Influenza
- Interventions
- Amantadine, Ribavirin, Oseltamivir, Oseltamivir
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2017-07-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01227967?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01227967-sae